Three inhibitors of the cyclin-dependent kinases CDK4/6, palbociclib, ribociclib, and abemaciclib, have emerged as highly promising therapies for the treatment of breast cancer and other solid tumors. These drugs are reported to have similar mechanisms of action although recent data suggest that abemaciclib exhibits distinct single-agent activity and toxicity. We compare their mechanisms of action using biochemical assays, mRNA profiling, mass spectrometry-based phosphoproteomics, and GR-based dose-response assays. We find that abemaciclib has activities not shared by palbociclib or ribociclib including: induction of cell death (even in pRb-deficient cells), arrest in the G2 phase of the cell cycle, and reduced drug adaptation. These activities appear to arise from inhibition of CDKs other than CDK4/6 including CDK2/Cyclin A/E and CDK1/Cyclin B. We propose that inhibition of these kinases by abemaciclib overcomes known mechanisms of resistance to CDK4/6 inhibition and may be therapeutically advantageous for patients whose tumors progress on palbociclib or ribociclib.
Introduction
Progression through the cell cycle is controlled by over a dozen distinct protein complexes involving cyclins and cyclin-dependent kinases (CDKs). Because dysregulation of the cell cycle is a hallmark of cancer, CDK inhibitors have been under development as therapeutics for many years but it is only recently that CDK4/6 inhibitors have emerged as highly promising drugs, particularly in breast cancer. CDK4 and CDK6 bind cyclin D early in the G1 phase of the cell cycle and phosphorylate the retinoblastoma protein (pRb). pRb is subsequently hyperphosphorylated by CDK2/cyclin E relieving its inhibitory activities against transcription factors of the E2F family which allows for S phase entry. Later in the cell cycle, CDK2/cyclin A and CDK1 in complex with either cyclin A or B promote entry and progression through G2 and mitosis. Multiple genetic changes in cancer cells disrupt critical steps in cell cycle regulation: amplification of CDK4, CDK6, cyclin D, or cyclin E are common in solid tumors including breast cancer 1, 2 . Deficiency in pRb function, which causes unregulated S phase entry and deletion of CDKN2A, which encodes the CDK4/6 inhibitor p16, are observed across all cancers 2, 3 .
First generation pan-CDK inhibitors are active against cell cycle regulators such as CDK1/2/4/6
and transcriptional regulators such as CDK7/9. These inhibitors arrest cells in both G1 and G2 and are broadly cytotoxic 2 . Clinical development of CDK inhibitors has been challenging largely because of poor therapeutic windows 2 and lack of selectivity. Subsequent generations of CDK inhibitors are designed to inhibit specific subsets of CDK proteins. In February 2015, the CDK4/6 inhibitor, palbociclib (PD0332991; Ibrance) 4 , received FDA approval for the management of hormone receptorpositive (HR + ) metastatic breast cancer 5, 6 (MBC). Approval was granted based on results of the PALOMA-1 trial, which demonstrated a significant improvement in progression-free survival of patients who received palbociclib with letrozole, as compared to letrozole alone; and palbociclib has subsequently exhibited activity in other malignancies [7] [8] [9] [10] . Subsequent to approval of palbociclib large clinical trials of two other CDK4/6 inhibitors, ribociclib (LEE011; Kisqali) 11 and abemaciclib (LY2835219; Verzenio) 12, 13 , have reported similar improvements in progression-free survival 4, 14 in HR+ 4 MBC, leading to their FDA approval and making CDK4/6 inhibitors some of the most promising new drugs for the treatment of breast cancer.
As observed with many other targeted therapies, however, acquired resistance to CDK4/6 inhibitors develops over time and nearly all initially responsive patients ultimately show disease progression 15 . The emergence of tumors resistant to CDK4/6 inhibitors is associated with multiple genomic alterations including loss of pRb function, amplification of CDK6, and of cyclin E, which promotes CDK2-dependent phosphorylation of pRb, thereby bypassing the requirement for CDK4/6 activity 2, 16 . At the single-cell level, high expression of cyclin E has been associated with high CDK2 activity post-mitosis, which appears to bypass a requirement for CDK4/6 for cell cycle reentry 17 .
Despite having the same nominal target and similar initial clinical indications, emerging evidence suggests that palbociclib, ribociclib, and abemaciclib have differential profiles in the clinic:
abemaciclib has single-agent activities and distinct adverse effects 18 . Currently, it is unknown if these drugs are therapeutically interchangeable and whether progression on one CDK4/6 inhibitor can be overcome by switching to a different inhibitor. The three drugs differ in relative activity against CDK4
and CDK6 and differences in target selectivity have been reported based on in vitro screening with ribociclib emerging as the most selective inhibitor and abemaciclib the least 19, 20 . The activity of abemaciclib against CDK9 has been reported to be inconsequential 21 whereas inhibition of DYRK/HIPK kinases has been reported to be a possible cause of cytotoxicity 22 . The importance of kinase selectivity in influencing anti-proliferative activity has not been established. All three agents are presented by their manufacturers as being similar in antitumor activity but with some differences in pharmacokinetics and toxicities: abemaciclib is dosed continuously whereas palbociclib and ribociclib are dosed intermittently to ameliorate hematologic toxicity 15 .
5 experimental approaches provide complementary insight into drug mechanisms of action. We find that palbociclib, ribociclib, and abemaciclib are distinct with respect to their biological activities, target profiles and ability to induce cytostasis and death in breast cancer cells of varying genotypes. Multiple lines of evidence show that the unique biological activities of abemaciclib arise from inhibition of kinases in addition to CDK4/6, notably CDK1/cyclin B and CDK2/cyclin E/A. Inhibition of these kinases is likely to be therapeutically beneficial and may provide rationale for using abemaciclib in patients whose disease progresses on, or does not respond to palbociclib or ribociclib, potentially including those whose cancers manifest loss of pRb function.
Results

Abemaciclib induces molecular signatures distinct from other CDK4/6 inhibitors
To compare mechanisms of action of palbociclib, ribociclib, and abemaciclib we performed transcriptional profiling (mRNA-seq) on a panel of seven breast cancer cell lines following 6 or 24 hours of drug exposure ( Fig. 1a and Supplementary Table S1 ). In all but pRb-deficient BT-549 cells, treatment with any of the three drugs was associated with a cluster (signature 1; Fig. 1a highlighted in red) of 87 significantly down-regulated genes (FDR < 0.2). When this signature was used to query the Broad Connectivity Map (CMAP) 24 , inhibitors of MEK (MAP kinase kinase) and palbociclib itself were the strongest hits (ribociclib and abemaciclib are absent from the CMAP dataset; Fig. 1b and Supplementary   Table S2 ). Signature 1 was enriched in genes of the Reactome set "Cell Cycle" (p=9.0×10 -50 ) and inhibition of MEK is anti-mitogenic in breast cancer cells, promoting arrest at the G1/S transition 25,26 .
We conclude that signature 1 reflects cell cycle arrest in G1, which is the expected effect of CDK4/6 inhibitors 5 . In all seven cell lines, including pRb-deficient BT-549 cells, treatment with abemaciclib in the low micromolar range induced a second transcriptional signature (signature 2; cyan cluster in Fig.   1a ) that was absent from ribociclib-exposed cells and only weakly present in cells exposed to 6 palbociclib. When the abemaciclib-specific transcript signature was compared to CMAP, the strongest hit was alvocidib (flavopiridol) and other pan-CDK inhibitors (Fig. 1c and Supplementary Table S3 ).
To better understand the origins of signature 2, we performed phosphoproteome profiling in MCF7 cells using liquid-chromatography mass spectrometry (LC/MS) with isobaric (TMT) tags 27 . We found that abemaciclib inhibited protein phosphorylation at a substantially greater number of phosphoprotein sites than did palbociclib (Fig. 1d, Supplementary Table S4 ). We used enrichment analysis 28 based on known kinase-substrate relationships (see Methods) to infer the activity of kinases whose down-regulation most likely accounted for the observed changes in the phosphoproteome following abemaciclib treatment. We found the inferred activities of CDK4, CDK6, and Aurora A/B kinases (AURKA/B) to be significantly down-regulated in both palbociclib and abemaciclib-treated cells. In addition, our analyses suggested that the activities of CDK1, CDK2, CaM-kinase II subunit alpha (CAMK2A), TTK, and polo-like kinase 1 (PLK1) are uniquely down-regulated by abemaciclib (Fig. 1e , Supplementary Table S5) . Thus, abemaciclib has a range of transcriptional and phospho-protein modulatory activities in breast cancer cells that are distinct from those of ribociclib or palbociclib.
Abemaciclib is active against multiple CDK/cyclin complexes
Inference of kinase activity from phosphoproteome data yields both direct and indirect drug targets and we performed in vitro assays to distinguish between them. KINOMEscan profiling against a panel of 468 recombinant kinases confirmed that ribociclib is the most selective CDK4/6 inhibitor and abemaciclib the least (Supplementary Fig. S1 and Table S6 ) 19, 20 . SelectScreen kinase activity and binding assays (Thermo Fisher, see Methods) showed that abemaciclib is the most potent inhibitor of CDK4 and CDK6 and that it is also active against multiple kinases that are weakly inhibited, or not inhibited, by palbociclib or ribociclib (Fig. 2a, Supplementary Fig. S2a and Table S7 ). These kinases include CDK2/cyclin A/E, CDK1/cyclin B, CDK7/cyclin H, CDK9/cyclin K/T1, GSK-3 beta (GSK3B), CAMK2A, and TTK ( Supplementary Fig. S2b ), targets that were also identified in transcriptional or 7 phosphoproteomic signatures. In comparison to the first-generation CDK inhibitor alvocidib, abemaciclib is similar in its activity against CDK2/cyclin A/E and about 10-fold less active against CDK1/cyclin B, CDK7/cyclin H, and CDK9/cyclin K/T1 (potentially explaining the improved toxicity profile of abemaciclib relative to pan-CDK inhibitors), whereas ribociclib and palbociclib are orders of magnitude less potent against these kinases. In general, results from KINOMEscan profiling, SelectScreen assays and in-cell profiling were concordant. Two exceptions were observed: CDK1, which is absent from the KINOMEscan panel, and CDK2, which appears to be a false negative finding, perhaps due to a lack of active CDK2/cyclin A and CDK2/cyclin E complexes 29 in the KINOMEscan assay.
When a drug inhibits multiple targets at different concentrations, as does abemaciclib, it is important to determine which targets are relevant at therapeutically achievable doses. We therefore computed the strength of the mRNA differential expression signatures 1 and 2 (which are associated with G1 arrest and pan-CDK inhibition respectively; Fig. 1b-c ) across all drugs, doses, and cell lines six hours after drug treatment (Fig. 2b) . We found that the score for signature 1 was high under all treated conditions, except in cells deficient in pRb (Fig. 2b, Fig. 3a) and is likely to be the result of CDK4/6 inhibition.
Abemaciclib elicited a second response at doses greater than 0.3 µM; this response was characterized by negative GR values and cell death (see Methods ; Fig. 3a) ; the higher-dose response was not observed in palbociclib-treated cells nor in the eight cell lines in which GR data were collected for ribociclib. As a result, the complete dose-response behavior of abemaciclib was significantly better fitted in most cell lines by the product of two sigmoidal curves (Fig. 3b, Supplementary Fig. S3 , and Methods). This behavior is consistent with inhibition of multiple targets with different potencies. The mid-point of these curves was offset to a similar degree as in vitro dose-response curves for CDK4/6 vs. Table S7 ). Overall, abemaciclib was substantially more efficacious than palbociclib in inhibiting and killing pRb-proficient cells of all subtypes, having a GR max value on average 0.52 lower (t-test P = 4.5×10 -9 ; Supplementary Table S9) . When we searched a set of 30 cell cycle regulators for those whose mRNA expression levels could discriminate between responsiveness to 9 palbociclib and abemaciclib in pRb-proficient cell lines, we found that a combination of elevated expression of CDKN1A (p21 -an inhibitor of CDK1/2/4/6), CDKL5 (a cyclin-dependent kinase targeted by abemaciclib and other pan-CDK inhibitors based on KINOMEscan data), CCNE1 (cyclin E1, which has been implicated in palbociclib resistance 15 ) and reduced expression of CDK9 (another abemaciclib and pan-CDK inhibitor target) comprised a strong preclinical pharmacogenomic predictor across the 26 cell lines tested (q 2 = 0.85, P = 2.9×10 -6 by leave-one-out cross validation; Fig. 3c ). Thus, abemaciclib has biological activities, including induction of cell death, that are not observed with palbociclib and ribociclib at doses that are well within a clinically accessible range based on human pharmacokinetic data. Abemaciclib also induced cell death in pRb-deficient cell lines at concentrations of 1 µM and above, whereas palbociclib was inactive ( Fig. 3a ; yellow lines).
CDK1/2 inhibition (Supplementary
Abemaciclib blocks cells in the G2 phase of the cell cycle and prevents adaptive response
Consistent with the known biology of CDK4/6 inhibition, abemaciclib, ribociclib, and palbociclib suppressed pRb phosphorylation and elicited G1 cell cycle arrest (Fig. 3d ). The differences in potency observed for these drugs matched the differences in IC 50 values for inhibition of CDK4/6 in biochemical assays (Fig. 2a) . A subset of abemaciclib-treated cells was also arrested in G2 at drug concentrations of 0.3 µM and above ( The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/211680 doi: bioRxiv preprint first posted online Nov. 7, 2017; showing that cells can escape from cytostasis induced by CDK4/6 inhibition ( Fig. 3d ) 17, 32 . In contrast, pRb phosphorylation remained low in cells exposed to 1 µM abemaciclib ( Table S10 ). In studies designed to assess long-term adaptation to drug, we observed that breast cancer cells grown for several months in the presence of 1 µM palbociclib had lower pRb and higher cyclin E levels than parental cells; these changes are expected to make cells relatively resistant to CDK4/6 inhibition ( Fig. 4b ). Palbociclib-adapted cells were cross-resistant to ribociclib ( Fig. 4c , Supplementary Fig. S6 and Table S11 ). In contrast, palbociclib-adapted cells were sensitive to abemaciclib at doses of 1 µM and above, consistent with the ability of abemaciclib to target 
Discussion
The demonstration that CDK4/6 inhibitors are effective for the treatment for HR+ metastatic breast cancer has resulted in over 100 clinical trials of palbociclib, ribociclib and abemaciclib in multiple . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a 11 malignancies. It has been assumed that the mechanisms of action of the three drugs are the same and that any discrepancies in efficacy and toxicity are due to differences in dosing schedules and relative potencies against CDK4 vs. CDK6. However, four lines of evidence in our work demonstrate that abemaciclib has activities not manifest by ribociclib and only weakly by palbociclib. First, treatment of breast cancer cells of different genotypes with abemaciclib induces not only transcriptional changes associated with G1 arrest, a property shared by palbociclib and ribociclib, but also induces changes in transcription that closely resemble the CMAP signatures for pan-CDK inhibitors such as alvocidib.
Second, exposing cells to abemaciclib results in more extensive changes in the phosphoproteome than exposure to palbociclib; kinase inference suggests that this is due in part to inhibition of CDK1 and CDK2 activity by abemaciclib. In vitro kinase assays confirm that CDK1/2 are direct targets of abemaciclib, placing abemaciclib, in regards to target selectivity, between the highly selective CDK4/6 inhibitors such as ribociclib and the first generation CDK inhibitors. Third, abemaciclib causes arrest of cells in both the G1 and G2 phases of the cell cycle and the drug is cytotoxic even in the absence of pRb; in contrast, cells exposed to palbociclib and ribociclib arrest only in G1 and cause little or no cell death.
Fourth, whereas abemaciclib durably inhibits cell proliferation, cultured cells adapt within 2-3 days of continuous exposure to palbociclib or ribociclib and resume proliferation.
Our results argue for a multi-faceted approach to the identification of kinase inhibitor targets.
Proteomic, transcriptional, biochemical, and phenotypic assays measure different aspects of cancer cell physiology and their use in combination was necessary in the current example for a complete picture of drug mechanisms of action. Proteomic and mRNA profiling showed that exposure of breast cancer cells to abemaciclib results in inhibition of CDK9, Aurora A/B kinases (AURKA/B), CaM-kinase II subunit alpha (CAMK2A), TTK, and polo-like kinase 1 (PLK1). Biochemical experiments showed that AURKA/B and PLK1 are most likely indirect targets of abemaciclib down-regulated as a consequence of G2 cell cycle arrest, whereas CAMK2A and TTK are direct targets of abemaciclib. Inhibition of GSK3B was observed in biochemical assays but was borderline significant by phosphoproteomic . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/211680 doi: bioRxiv preprint first posted online Nov. 7, 2017; analysis, perhaps reflecting the challenges of inferring changes in kinase activity from data that are inherently under-sampled 33 . The false negative finding in the widely used KINOMEscan data that abemaciclib does not interact with CDK2, may explain why biologic differences among CDK4/6 inhibitors are not widely appreciated.
In the case of a poly-selective drug such as abemaciclib it is important to determine the dose range at which inhibition of different targets is clinically relevant. There is no question that abemaciclib is the most potent of the three drugs against CDK4 and CDK6; biochemical and cell-based data show that abemaciclib inhibits these kinases at a lower concentration than either palbociclib or ribociclib do.
Relative to CDK4/6, abemaciclib is 10-to 100-fold less potent against CDK2 and CDK1, but we detect the cellular consequences of CDK1/2 inhibition at a concentration of 0.3 µM, well within its C max range in humans 7, 30 . Moreover, cells adapted to grow in the presence of palbociclib in culture, and cells from a patient whose disease progressed on ribociclib/letrozole still respond to abemaciclib. Abemaciclib is active in pRb-deficient cells at concentrations of 1 µM and above, but this activity is not observed with palbociclib or ribociclib. Given the concentrations required, it is not yet clear whether the activity of abemaciclib in pRb-deficient cells will translate into patients; clinical evaluation of RB1-mutant tumors will be required.
The current generation of CDK4/6 inhibitors benefits from a considerable investment in increasing selectivity, mainly as a means of reducing toxicity relative to earlier generation drugs 2, 34, 35 .
The remaining activity of abemaciclib against kinases other than CDK4/6 is likely to be of therapeutic benefit: blocking CDK2/cyclin E should mitigate resistance resulting from amplification of cyclin E 32, 36 and achieve a more complete response by targeting cells exiting mitosis with high CDK2 activity 17 ;
inhibition of CDK1/7/9 may also contribute to cell killing 37, 38 ; inhibition of mitotic kinases such as TTK may enhance tumor immunogenicity, a key contributor to drug response 39 ; and pRb-independent antiproliferative effects may reduce resistance stemming from pRb loss of function. These findings imply that it may ultimately be useful to select patients for abemaciclib treatment based on enhanced activity . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/211680 doi: bioRxiv preprint first posted online Nov. 7, 2017; 13 of CDK1/2 17 and/or loss of pRb. Abemaciclib may also be valuable in a post-palbociclib or postribociclib therapeutic setting and in other indications such as triple negative breast cancer.
Methods
Cell culture
Cell lines were purchased from ATCC, and verified by STR profiling 40 . MCF7, and Hs 578T
were maintained in Dulbecco's modified Eagle's medium (DMEM), T47D, BT-549, HCC1419 and HCC1806 in Roswell Park Memorial Institute medium (RPMI), and BT-20 in Eagle's minimum essential medium (EMEM) supplemented in each case with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S). Cells were tested routinely for mycoplasma. The PDX12-58 and HCI002 cultures were kindly provided by D. Stover and J. Brugge, and maintained in F-media containing ROCK inhibitor as described 41 with 1% P/S instead of gentamycin and fungizone. The MGH312 cell line was established as described 42 by direct culture of patient biopsy material, and initially plated in ACL4 with 5% FBS and 1% Antibiotic-Antimycotic. Once 100% tumor cellularity was achieved, the cells were transitioned to and maintained in RPMI with 10% FBS and 1% P/S. All cells were grown at 37°C, and 5% CO 2 .
Dose response measurements
Cells were plated at densities ranging from 500 to Fixed cells were imaged with a 10x objective using an Operetta microscope and analyzed using the Columbus image data storage and analysis system (Perkin Elmer, Waltham, MA). For most 
or with a flat line with the equation !" # ≡ !" EFG . The significance of each curve was assessed using an F-test and the most complex model with P < 0.05 was considered to best fit the data.
The parameters of the sigmoidal curve and the first phase of the biphasic curve are constrained as described in Hafner et al. 43 . In the biphasic curve, the parameter !IJ KL OPQ is constrained to be above 0.3 µM. The time-dependent GR values for Fig. 4a were evaluated over a 48-hour interval using the formula described previously 23 .
Phospho-pRb immunofluorescence and cell cycle analysis
Cells were seeded in 384-well plates, allowed to adhere for 24-36 hours, treated with CDK4/6 inhibitors, incubated for the desired amount of time then fixed in 4% formaldehyde, permeabilized with 0.5% Triton X-100 in PBS, and blocked with Odyssey blocking buffer (LI-COR, Lincoln, NE). Cells were labeled overnight at 4°C with a 1:800 dilution of anti-phospho-pRb Alexa-555 (Ser807/811) (Cell Signaling Technologies, Danvers, MA) and 2 µg/ml Hoechst 33342 (Sigma Aldrich, St. Louis, MO) prepared in Odyssey blocking buffer. Images were acquired with a Perkin Elmer Operetta microscope as described for the dose response measurements. Nuclei were segmented using Columbus software (Perkin Elmer, Waltham, MA) based on their Hoechst signal. DNA content was defined by the total Hoechst intensity within the nuclear mask. The average phospho-pRb intensity within the nuclear mask was determined, and a threshold for positivity was set by visually inspecting images of several control and treated wells per cell line.
.
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mRNA-seq
Cells were seeded in 12-well plates, and allowed to adhere for 24 hours at which time CDK4/6 inhibitors were added. Cells were lysed in the plates after 6 or 24 hours, and RNA was extracted using Applied Biosystems MagMax 96 total RNA isolation kit (Thermo Fisher Scientific, Waltham, MA) with DNAse digestion according to the manufacturer's protocol. RNA was checked for quantity with a NanoDrop (Thermo Fisher Scientific, Waltham, MA) and for quality using an Agilent Bioanalzyer instrument (with RIN value > 9.0). Libraries were prepared using a TruSeq Stranded mRNA sample preparation kit (Illumina, San Diego, CA) from 500 ng of purified total RNA according to the manufacturer's protocol in a reduced reaction volume. The finished cDNA libraries were assessed for quality using a Bioanalyzer and quantified with a Quant-iT dsDNA Assay kit (Thermo Fisher Scientific, Waltham, MA). The uniquely indexed libraries were multiplexed based on this quantitation and the pooled sample was quantified by qPCR using the Kapa Biosystems (Wilmington, MA) library quantification kit by the Molecular Biology Core Genomics Facility at the Dana-Farber Cancer Institute and sequenced on a single Illumina NextSeq500 run with single-end 75bp reads.
Reads were processed to counts through bcbio-Nextgen toolkit (https://github.com/chapmanb/bcbio-nextgen) 1.0.3a as follow: (1) Reads were trimmed and clipped for quality control in cutadapt v1.12; (2) Read quality was checked for each sample using FastQC 0.11.5; (3) High-quality reads were then align into BAM files through STAR 2.5.3a using the human assembly GRCh37; (4) BAM files were imported into DEXSeq-COUNT 1.14.2 and raw counts TPM and RPKM were calculated. R package edgeR 44 3.18.1 (R version 3.2.1) was used for differential analysis and generate log fold change, P-value and FDR.
Clustering analysis of the mRNA-seq data and L1000 signatures
Differential gene expression signatures were clustered along samples and genes based on the cosine distance for the log2(fold-change) using MATLAB default functions. log2(fold-change) values for genes with FDR values above 0.2 were set to zero. In figure 1a , the down-regulated gene clusters were defined manually based on the dendrogram of the genes. Each set of genes was used to query the set 'LINCS_L1000_Chem_Pert_down' in Enrichr 45 (see Supplementary Table 2 and 3) . Enrichment analysis was performed using the GSEA algorithm (gsea2-2.2.3.jar from Broad Institute 46 ) on the results used sets based on the name of 31 well-annotated drugs with -log 10 (P-value) as weight and the results was plotted in Fig. 1b,c. .
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The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/211680 doi: bioRxiv preprint first posted online Nov. 7, 2017; Phosphoproteomics mass spectrometry MCF7 cells were treated with 0.3 µM and 3 µM of palbociclib or abemacicblib or DMSO control for 1 hour in duplicate. For each sample, 4.5 mg of protein was utilized to perform serine and threonine phosphoproteome analysis. The samples were digested using Trypsin (Promega, Madison, WI), acidified and desalted using C18 Sep-Pak (Waters, Milford, MA). Phosphopeptides were enriched using the Thermo Scientific High-Select Fe-NTA Phosphopeptide Enrichment Kit. TMT was added as previously described 47, 48 . The sample was then enriched for phosphotyrosine-containing peptides using the pY-1000 antibody (Cell Signaling Technologies, Danvers, MA) coupled to Pierce Protein A Agarose beads (Thermo Fisher Scientific, Waltham, MA). The flow-through from the pY sample was kept and desalted for pS and pT analysis. 24 fractions (phosphoproteomics) were then desalted using the C18 StageTip procedure 49 . All MS analyses were performed on an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific, Waltham, MA) using a multi-notch MS3 method 50, 51 . Raw data were converted to mzXML and searched via Sequest 52 version 28 against a concatenated Uniprot database (downloaded 02/04/2014). Linear discriminate analysis was used to distinguish forward and reverse hits and reverse hits were filtered to an FDR of 1% at the protein level. Site localization confidence was assessed using the A-score method 53 . Reporter ion intensities were quantified and normalized as described earlier 48 .
Annotation of phosphopeptides with upstream kinases
16,300 phosphopeptides were detected across all conditions in MCF7 cells. The PhosphoSitePlus (PSP) database 54 , which contains curated annotations of upstream kinases, was queried using phosphopeptide sequence motifs and UniProt IDs as identifiers. Only ~6.3% of the phosphopeptides detected by phosphoproteomics had experimentally verifiable kinase annotations on PSP. The NetworKIN algorithm 55 that predicts upstream kinases, based on phosphopeptide sequences and STRING evidence, was used to identify kinases for the remaining phosphosites. A further 14% of phosphosites were annotated with predicted kinases (NetworKIN Score > 4). In total, 3145 phosphopeptides from 1242 proteins were annotated as being phosphorylated by 365 kinases (8297 kinase-peptide interaction pairs).
Differential kinase activity score using GSEA Based on the method described previously 28 , a kinase set library was assembled using the identified kinase-substrate relationships. The kinase set library is composed of kinases and their .
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The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/211680 doi: bioRxiv preprint first posted online Nov. 7, 2017; corresponding sets of phosphopeptide substrates. Only kinase sets that had more than 25 downstream phosphosites were used. The final kinase set library was composed of 60 kinases that phosphorylate 2597 peptides. For each phosphopeptide, the mean difference between the replicates and the maximum difference across conditions were computed. If the delta between the two scores was less than 1, then the phosphopeptide measurement was considered noisy and discarded, resulting in a final list of 9958 phosphopeptides (Supplementary Table 4 ). For each of the four treatment conditions, the average log2 (fold-change) was computed relative to the untreated control. Using the phosphopeptide log2(foldchange) values as input and the final kinase set library, GSEA algorithm (gsea2-2.2.3.jar from Broad Institute 46 ) was used to infer the enrichment score (P < 0.05 and FDR < 0.2). The enrichment score is a proxy metric for the differential activity of the kinases.
In vitro measurement of kinase inhibitory activity.
Ribociclib, palbociclib, and abemaciclib were assayed using the KINOMEscan® assay platform 
Western blots
20 µg of whole cell lysate (Fig. 4) .
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The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/211680 doi: bioRxiv preprint first posted online Nov. 7, 2017; Immunohistochemistry A 4 µm slice of a formalin-fixed, paraffin-embedded, biopsy of the liver lesion from which the MGH312 cell line was derived was mounted on a standard glass slide and stained for RB expression using a Leica Bond autostainer. The primary Rb antibody (clone 1F8; Bio SB, Santa Barbara, CA) was diluted 1:500 in Leica Bond Diluent and incubated for 15 min. The slide was counterstained with hematoxylin.
Identifying genes associated with differential efficacy of abemaciclib and palbociclib
Using the baseline mRNA expression of 30 genes linked to the cell cycle (cyclins, CDKs, CDKLs, and CDKNs), we built a multilinear model (MATLAB function 'fitglm') to predict the difference in GR values at 3.2 µM between palbociclib and abemaciclib for the pRb-proficient cell lines profiled in Fig. 3a . Predictors with non-significant coefficients (P > 0.05) were iteratively removed until only significant coefficients remained. A leave-one-out cross validation was performed with the remaining predictors to yield the results in Fig. 3c . Note that results were qualitatively similar if the pRb-deficient cell lines were included.
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